» Articles » PMID: 36163376

Underlying Mechanisms of Epithelial Splicing Regulatory Proteins in Cancer Progression

Overview
Specialty General Medicine
Date 2022 Sep 27
PMID 36163376
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is the second-leading disease-related cause of global mortality after cardiovascular disease. Despite significant advances in cancer therapeutic strategies, cancer remains one of the major obstacles to human life extension. Cancer pathogenesis is extremely complicated and not fully understood. Epithelial splicing regulatory proteins (ESRPs), including ESRP1 and ESRP2, belong to the heterogeneous nuclear ribonucleoprotein family of RNA-binding proteins and are crucial regulators of the alternative splicing of messenger RNAs (mRNAs). The expression and activity of ESRPs are modulated by various mechanisms, including post-translational modifications and non-coding RNAs. Although a growing body of evidence suggests that ESRP dysregulation is closely associated with cancer progression, the detailed mechanisms remain inconclusive. In this review, we summarize recent findings on the structures, functions, and regulatory mechanisms of ESRPs and focus on their underlying mechanisms in cancer progression. We also highlight the clinical implications of ESRPs as prognostic biomarkers and therapeutic targets in cancer treatment. The information reviewed herein could be extremely beneficial to the development of individualized therapeutic strategies for cancer patients.

Citing Articles

The role of ESRP1 in solid tumor development through the regulation of CD44 splicing and EMT processes.

Wang L, Zhang M, Zhao K, Yuan X, Zhao H, Liu Y Front Oncol. 2025; 15:1451130.

PMID: 40046628 PMC: 11881191. DOI: 10.3389/fonc.2025.1451130.


CPSF4-mediated regulation of alternative splicing of HMG20B facilitates the progression of triple-negative breast cancer.

Zhong G, Shen Q, Zheng X, Yu K, Lu H, Wei B J Transl Med. 2024; 22(1):1149.

PMID: 39731153 PMC: 11673668. DOI: 10.1186/s12967-024-06004-x.


Role of apoptosis repressor with caspase recruitment domain in human health and chronic diseases.

Ao X, Ji G, Zhang B, Ding W, Wang J, Liu Y Ann Med. 2024; 56(1):2409958.

PMID: 39351758 PMC: 11445919. DOI: 10.1080/07853890.2024.2409958.


CircRNAs in Pancreatic Cancer: New Tools for Target Identification and Therapeutic Intervention.

Weidle U, Nopora A Cancer Genomics Proteomics. 2024; 21(4):327-349.

PMID: 38944427 PMC: 11215428. DOI: 10.21873/cgp.20451.


Systematic analysis of the effects of splicing on the diversity of post-translational modifications in protein isoforms using PTM-POSE.

Crowl S, Coleman M, Chaphiv A, Jordan B, Naegle K bioRxiv. 2024; .

PMID: 38260432 PMC: 10802621. DOI: 10.1101/2024.01.10.575062.


References
1.
Wang M, Yu F, Zhang Y, Chang W, Zhou M . The Effects and Mechanisms of Flavonoids on Cancer Prevention and Therapy: Focus on Gut Microbiota. Int J Biol Sci. 2022; 18(4):1451-1475. PMC: 8898378. DOI: 10.7150/ijbs.68170. View

2.
Wang M, Chen X, Yu F, Ding H, Zhang Y, Wang K . Extrachromosomal Circular DNAs: Origin, formation and emerging function in Cancer. Int J Biol Sci. 2021; 17(4):1010-1025. PMC: 8040306. DOI: 10.7150/ijbs.54614. View

3.
Shan P, Yang F, Qi H, Hu Y, Zhu S, Sun Z . Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer. Cancer Res. 2021; 81(15):4027-4040. DOI: 10.1158/0008-5472.CAN-20-0922. View

4.
Liu Y, Ao X, Zhou X, Du C, Kuang S . The regulation of PBXs and their emerging role in cancer. J Cell Mol Med. 2022; 26(5):1363-1379. PMC: 8899182. DOI: 10.1111/jcmm.17196. View

5.
Jonckheere S, Adams J, De Groote D, Campbell K, Berx G, Goossens S . Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs. 2021; 211(2):157-182. DOI: 10.1159/000512218. View